AR122129A1 - Vacuna de tau para el tratamiento de la enfermedad de alzheimer - Google Patents

Vacuna de tau para el tratamiento de la enfermedad de alzheimer

Info

Publication number
AR122129A1
AR122129A1 ARP210101372A ARP210101372A AR122129A1 AR 122129 A1 AR122129 A1 AR 122129A1 AR P210101372 A ARP210101372 A AR P210101372A AR P210101372 A ARP210101372 A AR P210101372A AR 122129 A1 AR122129 A1 AR 122129A1
Authority
AR
Argentina
Prior art keywords
tau
alzheimer
disease
compositions
peptides
Prior art date
Application number
ARP210101372A
Other languages
English (en)
Spanish (es)
Inventor
Robin Barbour
Gene Kinney
Wagner Zago
Tarlochan S Nijjar
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of AR122129A1 publication Critical patent/AR122129A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP210101372A 2020-08-07 2021-05-19 Vacuna de tau para el tratamiento de la enfermedad de alzheimer AR122129A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063062971P 2020-08-07 2020-08-07

Publications (1)

Publication Number Publication Date
AR122129A1 true AR122129A1 (es) 2022-08-17

Family

ID=80118379

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101372A AR122129A1 (es) 2020-08-07 2021-05-19 Vacuna de tau para el tratamiento de la enfermedad de alzheimer

Country Status (12)

Country Link
US (1) US20230302127A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192583A4 (cg-RX-API-DMAC10.html)
JP (2) JP2023536746A (cg-RX-API-DMAC10.html)
KR (1) KR20230080398A (cg-RX-API-DMAC10.html)
CN (1) CN117751132A (cg-RX-API-DMAC10.html)
AR (1) AR122129A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021321206A1 (cg-RX-API-DMAC10.html)
CA (1) CA3188458A1 (cg-RX-API-DMAC10.html)
IL (1) IL300346A (cg-RX-API-DMAC10.html)
MX (1) MX2023001501A (cg-RX-API-DMAC10.html)
TW (1) TW202221022A (cg-RX-API-DMAC10.html)
WO (1) WO2022031342A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN102596236B (zh) * 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
WO2015098963A1 (ja) * 2013-12-26 2015-07-02 東亞合成株式会社 カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド
WO2015165961A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2016154522A1 (en) * 2015-03-25 2016-09-29 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
KR20250058066A (ko) * 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
SG11201910066QA (en) * 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
JP2020536946A (ja) * 2017-10-16 2020-12-17 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
TWI859197B (zh) * 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體

Also Published As

Publication number Publication date
WO2022031342A1 (en) 2022-02-10
KR20230080398A (ko) 2023-06-07
EP4192583A1 (en) 2023-06-14
MX2023001501A (es) 2023-03-08
EP4192583A4 (en) 2025-02-12
CN117751132A (zh) 2024-03-22
JP2026120788A (ja) 2026-07-22
AU2021321206A1 (en) 2023-03-09
US20230302127A1 (en) 2023-09-28
JP2023536746A (ja) 2023-08-29
IL300346A (en) 2023-04-01
CA3188458A1 (en) 2022-02-10
TW202221022A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
CL2025000674A1 (es) Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer
MX2023001501A (es) Vacuna tau para tratamiento de enfermedad de alzheimer.
AR123188A1 (es) Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer
AR122127A1 (es) VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
MX2023003008A (es) Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer.
US20160220640A1 (en) Methods and compositions for increasing neurogenesis and angiogenesis
US20250255939A1 (en) Methods and compositions for inducing neural plasticity
US20250177490A1 (en) Compositions and methods for promoting islet viability and enhancing insulin secretion
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
Mowbray et al. Gene expression of AvBD6-10 in broiler chickens is independent of AvBD6, 9, and 10 peptide potency
MX2023003007A (es) Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias.
Tucker et al. Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide
US20140329758A1 (en) Peptide inhibitors for mediating stress responses
AR108790A1 (es) Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria
US11524052B2 (en) Compositions and methods for treating neurological and other disorders
US20230181692A1 (en) Compositions for use in the treatment of neurological disease
WO2016060190A1 (ja) アミロイドβ蛋白質により誘発される認知障害の治療剤
US10660935B2 (en) Methods for ameliorating memory impairment in a memory disorder caused by neuronal cell death or Abeta aggregation using a peptide
JP7315964B2 (ja) Ａβタンパク質特異的産生抑制剤
EA201900478A1 (ru) Способ лечения воспалительных процессов суставов и простатита
AR130826A1 (es) Método para tratar el cáncer
CN118806876A (zh) 眼镜蛇神经毒素及其制剂在制备预防和/或治疗阿尔茨海默病的药物中的用途
BR112018077467A2 (pt) composição de matéria, composição farmacêutica, complexo, kit, vetor de expressão, método para fazer um peptídeo, método para reduzir ou inibir agregação de ¿-sinucleína (seq id no: 1), método para modular o tamanho ou a taxa de crescimento de fibrilas amiloides de ¿-sinucleína ou a taxa de espalhamento de fibrila amiloide de ¿-sinucleína, método para observar a presença ou ausência de fibrilas amiloides de ¿-sinucleína em uma amostra biológica, peptídeo modificado, método para inibir semeadura alfa-sinucleína, e método para reduzir ou inibir agregação de uma ¿-sinucleína mutante